Is that the clue why Big Rock Partners Acquisition Corp. (BRPA) skyrocketed in the AH?

Several times recently, the Big Rock Partners Acquisition Corp. (NASDAQ: BRPA), the stock has increased in value for simple business news or no news at all. BRPA, shares jumped more than 50% to $6.25 in the late hours.

However, last week, a special purpose acquisition company announced that it has entered into a binding agreement to acquire NeuroRx, Inc. Under the terms of the deal, NeuroRx and Big Rock will merge, and the company will continue to trade on the Nasdaq Stock Market under the symbol “NRXP.”

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Read More

The transaction is expected to take place in the first or second quarter of 2021. Being listed on Nasdaq, NeuroRx expects increased access to capital to help it continue to develop its innovative drug pipeline targeting Central Nervous System, Psychiatry, and Respiratory Disease.

NeuroRx is a clinical-stage, small molecule pharmaceutical company specializing in treating central nervous system disorders and life-threatening pulmonary diseases. The company’s two main drugs are “ZYESAMI,” which is intended to treat COVID-related respiratory failure, and “NRX-101,” meant for treating suicidal bipolar depression and PTSD.

Most Popular

Related posts